Nomura Holdings
VERV

Nomura Holdings’s Verve Therapeutics VERV Stock Holding History

Nomura Holdings’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-64,730
Closed -$296K – 1972
2025
Q1 		$296K Sell
64,730
-62
-0.1% -$415 ﹤0.01% 1606
2024
Q4 		$365K Buy
64,792
+19
+0% +$107 ﹤0.01% 1906
2024
Q3 		$314K Sell
64,773
-10
-0% -$58 ﹤0.01% 1333
2024
Q2 		$316K Buy
64,783
+46,037
+246% +$289K ﹤0.01% 1441
2024
Q1 		$249K Sell
18,746
-330
-2% -$4.38K ﹤0.01% 1408
2023
Q4 		$266K Buy
19,076
+900
+5% +$11.2K ﹤0.01% 1511
2023
Q3 		$241K Sell
18,176
-900
-5% -$14.5K ﹤0.01% 1225
2023
Q2 		$358K Sell
19,076
-1,250
-6% -$20.8K ﹤0.01% 1097
2023
Q1 		$293K Sell
20,326
-12,521
-38% -$245K ﹤0.01% 1199
2022
Q4 		$634K Buy
+32,847
New +$870K ﹤0.01% 926

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nomura Holdings's VERV Position: Q2 2025 in Review

Nomura Holdings sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 64,730 shares — an estimated $296K sold.

Nomura Holdings first reported a position in VERV in Q4 2022 and held it in 10 quarters. The position peaked at $634K in Q4 2022. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Nomura Holdings reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nomura Holdings sold 64,730 Verve Therapeutics shares in Q2 2025, an estimated $296K.
  • Nomura Holdings first reported a position in Verve Therapeutics in Q4 2022 and held it in 10 quarters.
  • Nomura Holdings's Verve Therapeutics position peaked at $634K in Q4 2022.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Nomura Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.